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Abstract
Background: Restenosis after percutaneous transluminal angioplasty (PTA) of the superficial femoral artery (SFA)
may occur in 45% of patients at 2 years follow-up. Paclitaxel-coated balloons have been found to reduce
neointimal hyperplasia, and thus reduce restenosis. Recently, the LegflowW paclitaxel-coated balloon (Cardionovum
Sp.z.o.o., Warsaw, Poland) (LPEB) has been introduced. This balloon is covered with shellac, a Food and Drug
Administration (FDA) approved natural resin, to obtain an equally distributed tissue concentration of paclitaxel. The
RAPID trial is designed to assess restenosis after PTA using the Legflow balloon combined with nitinol stenting
versus uncoated balloons with nitinol stenting in SFA lesions >5 cm.
Methods/Design: A total of 176 adult patients with Rutherford class 2 to class 6 symptoms due to intermediate
(5–15 cm) or long (>15 cm) atherosclerotic lesions in the SFA will be randomly allocated for treatment with LPEB
with nitinol stenting or uncoated balloon angioplasty with stenting. Stenting will be performed using the SuperaW
stent in both groups (IDEV Technologies Inc., Webster, TX). The primary endpoint is the absence of binary restenosis
of the treated SFA segment. Secondary outcomes are target lesion revascularization (TLR), clinical and hemodynamic
outcome, amputation rate, mortality rate, adverse events, and device-specific adverse events. Follow up consists of four
visits in which ankle-brachial indices (ABI), toe pressure measurements, and duplex ultrasound (DUS) will be performed.
Furthermore, a peripheral artery questionnaire (PAQ) will be completed by the patients at each follow-up. In the event
that DUS reveals a symptomatic >50% restenosis, or a >75% asymptomatic restenosis, additional digital subtraction
angiography will be performed with any necessary re-intervention.
(Continued on next page)
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Discussion: The RAPID trial is a multicenter randomized controlled patient blind trial that will provide
evidence concerning whether the use of the Legflow paclitaxel/shellac coated balloons with nitinol stenting
significantly reduces the frequency of restenosis in intermediate and long SFA lesions compared to standard
PTA and stenting.
Trial registration: ISRCTN47846578
Background
Atherosclerotic lesions in the superficial femoral artery
may cause intermittent claudication (IC) and critical limb
ischemia (CLI), leading to serious complications such as
tissue loss, amputation and even death. Revascularization
relieves symptoms and may prevent or delay these compli-
cations. Over the last decades, endovascular repair has
become the preferred treatment for femoral arterial ob-
structive disease [1,2]. No definitive consensus has emerged
concerning the best endovascular strategy, like the added
value of stenting. Literature is most supportive of balloon
angioplasty with stenting in longer segment lesions in the
superficial femoral artery (SFA). However, even with stenting
reported restenosis rates are between 35% and 45% after
one and two years follow-up respectively [3,4]. Paclitaxel-
coated balloons have been found to reduce restenosis in the
Thunder and FEMPAC trials [5,6]. Recently, the LegflowW
paclitaxel eluting balloon (Cardionovum Sp.z.o.o., Warsaw,
Poland)(LPEB) has been introduced. This paclitaxel eluting
balloon is covered with shellac, to obtain an equally distrib-
uted tissue concentration of paclitaxel, reaching an optimal
dose at a short inflation time of 45 seconds.
So far, no randomized controlled trials have been per-
formed using the LegflowW coated balloon in intermediate
and long lesions in the superficial femoral artery combined
with primary stenting in both treatment arms.
Hypothesis
We hypothesize that the LegflowW paclitaxel eluting balloon
in combination with nitinol stents will lead to a significantly
lower restenosis rate when compared to conventional un-
coated balloon angioplasty combined with the same nitinol
stents in treatment of intermediate (≥5 cm and <15 cm)
and long-segment (≥15 cm) SFA lesions.
Methods/Design
Study design
This study is a randomized, controlled, patient-blind,
multicenter trial (Figure 1).
Primary endpoint
The primary endpoint is the absence of binary restenosis
at two years. This is defined as the percentage of limbs
with absence of hemodynamically significant obstruction
- De novo symptomatic lesion in superficial
femoral artery >5cm. Rutherford 2-6 
- Atleast one patent below the knee artery 
Lesion crossed by guidewire 
Legflow® Paclitaxel eluting balloon + 
nitinol stent 
Standard PTA balloon +nitinol stent  
Randomization
Follow-up 1,6,12,24 months with: 
- DUS
- ABI
- Toepressure
- Periferal artery questionaire
Follow-up 1,6,12,24 months with: 
- DUS
- ABI
- Toepressure
- Periferal artery questionaire
Figure 1 Flow diagram for inclusion and treatment. Legend: DUS, duplex ultrasound; ABI, Ankle-Brachial index.
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in the target lesion after endovascular treatment as
indicated below:
• >50% measured as proximal peak velocity ratio
(PVRprox) ≥2.4 at duplex scanning
• >50% stenosis on digital subtraction angiography
(DSA).
Secondary endpoints
1. Immediate outcome
a. Device success. Defined as exact deployment of
the device, according to the instructions for use,
using the assigned device only.
b. Technical success. Defined as successful vascular
access and completion of the endovascular
procedure and immediate morphological success
with less than 30% residual diameter reduction
and <10 mmHg translesional pressure gradient of
the treated lesion on completion.
c. Procedural success. Defined as the combination
of technical success, device success and absence
of procedural complications.
2. Clinical outcome
a. Distribution of Rutherford stages during follow-
up as compared to baseline.
b. In patients with IC: Improvement in claudication
onset time (COT) and absolute claudicating time
(ACT).
c. Improvement in disease-related health status,
functioning and quality of life. As defined by the
Peripheral Artery Questionnaire (PAQ).
d. Primary sustained clinical success rate. Defined as
improvement by at least one Rutherford category,
except for those with actual tissue loss (category
5 and 6), who must at least improve to the level
of IC (category 3), in surviving patients, with
preserved limb, without the need for target lesion
revascularization (TLR).
e. Secondary sustained clinical success rate. Defined
as improvement by at least one Rutherford
category, expect for those with actual tissue loss
(category 5 and 6), who must at least improve to
the level of IC (category 3), in surviving patients,
with preserved limb, including the need for TLR.
f. Primary sustained resolution of symptoms from
peripheral arterial occlusive disease (PAOD) rate.
Defined as sustained absence of IC or CLI
(Rutherford 0), in surviving patients, with
preserved limb, without the need for TLR.
g. Secondary sustained resolution of symptoms from
PAOD rate. Defined as sustained absence of IC or
CLI (Rutherford 0), in surviving patients, with
preserved limb, including the need for TLR.
h. Clinical deterioration rate. Defined as downgrade
of more than one category on the Rutherford
classification after endovascular treatment
(improvements after subsequent TLR/ target-
extremity revascularization (TER) are not included).
3. Hemodynamic outcome
a. Mean and median Ankle to Brachial Index (ABI)
during follow-up as compared to baseline.
b. Immediate hemodynamic improvement. Defined
as post-procedural increase in ABI of ≥0.10 or to
an ABI ≥0.9.
c. Primary sustained hemodynamic improvement.
Defined as sustained increase in ABI of ≥0.10 or
to an ABI ≥0.9, in surviving patients, with
preserved limb, without the need for TLR.
d. Secondary sustained hemodynamic improvement.
Defined as sustained increase in ABI of ≥0.10 or
to an ABI ≥0.9, in surviving patients, with
preserved limb, including the need for TLR.
4. Re-occlusion rate. Defined as complete occlusion of
the initially treated target-lesion.
5. Target-lesion revascularization (TLR) rate. Defined
as the rate and frequency of the need for repeated
procedures (endovascular or open surgical) due to a
problem arising from the target-lesion (+1 cm
proximally and distally to include edge phenomena)
in surviving patients with preserved limb. This will
be reported as a percentage for each reported
frequency (for example, 12% with 1 TLR, 4% with 2
TLR, etcetera)
6. Target-extremity revascularization (TER) rate.
Defined as the rate and frequency of the need for
repeated procedures (endovascular or open surgical)
due to a problem arising in the treated limb, but not
at the target-lesion site in surviving patients with
preserved limb.
7. Mortality rate. Mortality rate associated with the
endovascular procedure (that is, mortality within
30 days post-procedure or mortality during a
hospitalization >30 days due to the procedure) will
be reported separately, as well as overall mortality.
8. Amputation rate. Divided in minor (below the ankle)
and major (through or above the ankle). Major
amputation is subdivided in below-the-knee,
through-knee, and transfemoral. Planned and
unplanned amputations will be reported separately.
Planned amputations are defined as amputations
that were be planned prior to the revascularization
procedure (that is, when the revascularization
procedure is performed to improve the
vascularization (and thereby healing potential) of the
planned amputation wound).
9. Rate of device-specific problems (for example, stent
fracture, stent migration, balloon rupture).
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Definitions
Definitions of endpoints and parameters are in concord-
ance with the proposed definitions by the Define group, a
multidisciplinary team from various specialties involved in
PAOD therapies, from Europe and the USA, which has
made definitions for more standardized reporting in
studies for endovascular treatment of PAOD [7]. There
will be a two-year follow-up for all primary and second-
ary endpoints.
Patients
A total of 176 patients aged over 18 years, with symptom-
atic atherosclerotic intermediate or long-segment obstruc-
tions of the superficial femoral artery, Rutherford category
2 to 6, will be randomized.
Eligibility criteria
Inclusion criteria
1. Age over 18
2. Symptomatic, atherosclerotic intermediate (≥5 cm
and <15 cm) and long (≥15 cm) lesions of the
superficial femoral artery.
3. Rutherford class 2 to 6
4. At least one patent below-the-knee artery with
uninterrupted flow to the pedal arch.
5. Signed informed consent
6. Randomization will be performed after advancement
of a guide wire across the target SFA lesion.
Exclusion criteria
1. Life expectancy less than one year.
2. Previous endovascular or surgical treatment of the
target superficial femoral artery
3. Inability to comply with the follow-up schedule.
4. Mental disability that hinders the ability to
understand and comply with the informed consent.
5. Pregnancy or breast-feeding.
6. Severe renal failure (e-GFR <30 mL/min/1.73 m2).
7. Known allergy to iodinated contrast agents.
8. Contra-indication for anti-coagulation (aspirin as
well as clopidogrel).
9. (Acute) limb ischemia caused by SFA or popliteal
artery aneurysmal disease
10.Obstruction caused by SFA or popliteal artery
dissections
Randomization
Central randomization will be performed by block random-
ization with use of an automated web-based random-
ization tool.
Ethics
This study is conducted in accordance with the
principles of the Declaration of Helsinki and Good
Clinical Practice guidelines. The study protocol was
approved by the Ethics Committee (METC) of the
St. Antonius Hospital Nieuwegein (R-12.009). Written
informed consent will be obtained from all patients,
before randomization.
Safety and quality control
Data safety monitoring board
The Data Safety Monitoring Board (DSMB) is composed
of three members: one independent vascular surgeon
and two independent interventional radiologists. None
of the members is working in one of the hospitals that
will include patients. The role of the DSMB is to review
safety and to make recommendations regarding the
conduct of the study to the steering committee and to
the accredited METC that approved the study protocol.
Adverse and serious adverse events
Adverse events (AE) are defined as any undesirable ex-
perience occurring to a subject during the clinical trial,
whether or not considered related to the investigational
treatment. All adverse events and serious adverse events
reported spontaneously by the subject or observed by
the investigator or his staff will be recorded using an
adverse events form during admission and throughout
24 months of follow-up. AEs can be classified as mod-
erate or serious and will be recorded on the case record
forms (CRFs). A description of the event, start date,
end date, whether suspected device-related, any action
taken, and the outcome will be described.
A serious adverse event (SAE) is any AE that results in
death, or that:
1. results in a life-threatening illness or injury.
2. results in permanent impairment of a body structure
or bodily function.
3. requires inpatient hospitalization or prolonged
hospitalization.
4. results in medical or surgical intervention to prevent
permanent impairment to body structure or bodily
function.
Serious adverse events will be classified according to
the following four categories:
1. Access complications (may be at the access site or
distal to it): Hematoma/bleeding, arterial/venous
occlusion/thrombosis, severe vasospasm, intimal
injury/dissection, pseudoaneurysm, arteriovenous
fistula, vascular perforation or rupture, arterial
embolization distal to puncture site.
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2. Treatment site complications (may be at the
treatment site or proximal or distal to it):
Hematoma/bleeding, arterial/venous occlusion/
thrombosis, severe vasospasm, intimal injury/
dissection, pseudoaneurysm, AV fistula, vascular
perforation or rupture, arterial embolization distal to
treatment site.
3. Organ-specific complications:
a. Neurological: TIA, minor and major stroke, seizure.
b. Cardiovascular: Hypotension or hypertension
requiring treatment, arrhythmia requiring
treatment, myocardial ischemia/infarction,
chronic heart failure.
c. Respiratory: Profound hypoxia, pulmonary
edema, respiratory arrest, pulmonary embolism,
pneumothorax.
d. Gastrointestinal: Gastric bleeding, pancreatitis,
peritonitis, abscess, perforation of hollow viscus.
4. Systemic complications: Allergic/anaphylactic
reaction, renal failure, idiosyncratic reaction to drug,
fluid/electrolyte imbalance.
Data on AEs and SAEs will be reported to the
DSMB and to the accredited METC via the
“Toetsingonline” page of the website of the Central
Committee on Research involving Human Subjects
(www.ccmo.nl).
Statistical analysis
Sample size calculation
Based on the present literature, a two-year restenosis
rate of 45% in the standard group and a two-year resten-
osis rate of 20% in the LPEB group may be expected
[3,4]. Given a power of 90% based on a two-tail test with
an alpha error level of 0.05, a beta error level of 0.1, an
anticipated loss to follow-up of 10%, and a sample size
of 88 patients per group, a total of 176 patients will be
needed. The analysis will be performed in accordance
with intention-to-treat principle. For the primary end-
point, a chi squared test for univariate analysis and Cox
proportional hazards model will be assessed to investi-
gate the relation between co-variants and the endpoint.
An interim analysis on the primary end point (that is,
efficacy) will be at 6 months follow-up of the first 50
consecutive patients by the DSMB. The Peto approach
will be followed, meaning that the study will only be
stopped for beneficial effects in case of a P <0 .001 [8].
The study will not be stopped in case of futility. There
will be a blinded outcome assessment by the DSMB for
all patients. Missing data will be analyzed using mul-
tiple imputation.
Intervention
The aim of the treatment is to obtain a patent superficial
femoral artery, with uninterrupted flow to the pedal arch.
Therefore not only the SFA will be treated, but if indicated,
the aorto-iliac inflow arteries may be treated additionally
during the same procedure. However, for randomization
of the SFA stenosis or occlusion, it is mandatory that
the inflow artery is treated successfully (that is, a residual
obstruction <30% or a translesional mean pressure gra-
dient <10 mmHg). This strategy corresponds with daily
practice. Invasive translesional pressure gradients will
be measured to determine lesion characteristics.
Before the start of the interventional procedure, a
radiopaque ruler must be placed under the leg to measure
the length of the lesion. If the common femoral artery
(CFA) needs additional treatment, the physician is free to
choose a contralateral (cross-over) or ipsilateral (antegrade)
technique. At the start of the procedure 40 ml of arterial
blood will be drawn from the introducer sheath, just after
sheath placement and samples will be collected by the
Laboratory of Experimental Cardiology in the context of
the Athero Express Biobank Study which has been ap-
proved in the past (study nr. C-01.18). DSA images will
be made of the ipsilateral limb in at least two planes
with a minimum of 30 degrees difference in angulation
before and after angioplasty. Radiographic single shots
must be made during inflation of the balloons, of the
implanted stents, and during post-dilatation of the stents,
if performed. All single shots must be stored.
Patients will be randomized to either the LPEB or
conventional balloon PTA when the guide wire has suc-
cessfully passed the SFA lesion. Predilatation with an
undersized uncoated PTA balloon will be performed.
This will be followed by PTA with LPEB or uncoated
balloon, as randomized. To avoid geographic miss this
balloon dilatation has to be performed with a longer
balloon compared to the length of the lesion itself. Infla-
tion time in either group is at least 45 seconds, allowing
adequate drug transfer in case of the LPEB. Next an
adequately sized stent (maximum 10% oversizing com-
pared to the diameter of the native SFA below the le-
sion) is implanted according to instructions for use
(IFU). Stenting will be performed using the SuperaW
wire interwoven nitinol stent (IDEV Technologies Inc.,
Webster TX). In cases of stenosis including the origin
of the SFA, a SmartW stent (Cordis J&J, Bridgewater
NJ) will be implanted. The stent must be longer than
the treated lesion, but shorter than the balloon that has
been used for angioplasty. It is strongly preferred to
use one stent to treat the entire SFA lesion. If necessary
the stent may be tailored with an additional in-stent bal-
loon dilatation at the discretion of the interventionalist,
using a standard (non-drug eluting) PTA balloon of
adequate size. A duplex scan of the target lesion must
be performed before discharge.
All pre-procedural, procedural, and follow-up imaging
studies (magnetic resonance angiogram (MRA), DSA) will
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be assessed using CAAS QVA 3D (Quantitative Vascular
Analysis) software in a core lab.
Follow-up
All patients receive aspirin 100 mg daily and simvastatin
40 mg daily, indefinitely, starting at least one week prior
to the procedure. During the intervention all patients re-
ceive 5000 international units of heparin. After the inter-
vention all patients receive additional clopidogrel 75 mg
daily for a period of 3 months. Thereafter, aspirin will be
continued.
At 1, 6, 12, and 24 months, patients will undergo
treadmill test, ABI, toe pressure, and TcpO2 measure-
ments of at least the ipsilateral leg. Any complication
that occurred within the first 30 days will be recorded.
Patients will be asked to fill in a validated peripheral ar-
tery questionnaire (PAQ) [9,10]. Furthermore, DUS of
the treated SFA will be performed. In case DUS reveals a
symptomatic >50% restenosis, or a >75% asymptomatic
restenosis additional digital subtraction angiography will
be performed with any necessary re-intervention.
Data collection
Data will be collected by means of an e-CRF during
treatment in the participating centers. The CRF will
be completed prospectively during hospital admission
and follow-up. After that, the CRFs will be forwarded
to the data coordinating center. There will be regular
contact between the study coordinators and the par-
ticipating centers.
Discussion
Prevention of restenosis remains a major challenge in
the treatment of peripheral arterial occlusive disease.
The use of paclitaxel has proven to inhibit neointimal
growth and thus reduce restenosis after percutaneous
coronary interventions and SFA lesions [4-6,11]. Recent
literature provides evidence that stenting after PTA is
of importance to reduce restenosis in intermediate and
long-segment SFA lesions [2,3]. The paclitaxel-coated
balloons used in previous studies utilize iopromide as
excipient, whereas in the current study shellac is the
excipient. It is this carrier that distinguishes this bal-
loon from other drug eluting balloons. Shellac might be
superior to other excipients in binding the paclitaxel to
the balloon and will facilitate a fast and effective deliv-
ery of paclitaxel in the arterial wall. In this way lower
doses of paclitaxel are needed and shorter inflation time of
the balloon itself is required [12]. Furthermore the results
of the Thunder and Fempac trials are difficult to inter-
pret on account of the significant heterogeneity in the
study populations. Lesions of all lengths were randomized
for treatment with paclitaxel-covered balloon or uncoat-
ed balloon with bailout stenting using different stents.
Furthermore previously treated obstructions and in stent
restenosis were included, as well as de novo SFA lesions
[4,5]. The RAPID study is the first study designed to
assess absence of binary restenosis after treatment of
SFA lesions >5 cm with a paclitaxel/shellac-coated bal-
loon versus uncoated balloon with stenting in both
treatment arms. One of the strengths of this study is
that all patients will be treated using the SuperaW inter-
woven nitinol stent (IDEV Technologies Inc., Webster
TX), except for lesions involving the origin of the SFA,
which will be treated with a Smart stent (Cordis J&J,
Bridgewater, NJ). Furthermore the LegFlowW is a recently
introduced device that requires a short inflation time of
45 seconds, and may reduce aneurysm formation in the
treated segment due to the limited exposure to pacli-
taxel. Aneurysm formation is described with the use of
paclitaxel in drug eluting stents in some case reports.
[13-15] Shellac is used in this device to obtain an
equally distributed tissue concentration of paclitaxel,
reaching an optimal dose at a short inflation time. This
results in reduced neointimal growth, and reduces the
risk of restenosis. In porcine models paclitaxel/shellac-
coated balloons show a higher tissue concentration over
time than other paclitaxel balloons, requiring a shorter
inflation time for optimal tissue concentrations [12].
Recently, the use of the DIOR 2 balloon (also covered
with paclitaxel/shellac and used in the coronary arter-
ies) for in-stent restenosis of small coronary arteries
proved safe at one year follow-up. TLR of the treated
segments in this study was 12% [7].
The target lesions characterization will be using an
anatomical description as advised by the Define group
[16]. One of the drawbacks of the current Inter-Society
Consensus for the Management of Peripheral Arterial
Disease (TASC II) classification is the lack of inclusion
of baseline anatomic characteristics of the target (in
this trial the SFA) lesion itself and that it combines
femoropopliteal lesions as well as below the knee le-
sions within the same nomenclature [1]. Therefore, the
TASC classification, although commonly utilized, may
not be ideal. All devices, guide wires and catheters have
CE-approval (1434-MDD-32/2011). The shellac used on
the catheter is recognized as safe by the FDA (E904).
The RAPID trial is a randomized controlled patient
blind trial that will provide evidence of whether the
use of paclitaxel/shellac coated balloons with stenting
reduces the frequency of restenosis in intermediate
(5–15 cm) and long (>15 cm) lesions of the superficial
femoral artery.
Trial status
Approval of the study protocol from the central medical
ethical committee has been obtained. Currently 20 patients
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are enrolled in the RAPID trial. The projected completion
date for this trial is August 2015.
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